TTOO - T2 Biosystems reports Q1 results
T2 Biosystems (TTOO): Q1 GAAP EPS of -$0.07.Revenue of $7M (+174.5% Y/Y)Increased U.S. sepsis test utilization by 85% compared to the prior year period, resulting in a first quarter annualized test run rate of approximately $111,000 per legacy sepsis instrumentSold 4 T2Dx® Instruments during the first quarter, including 1 in the U.S. and 3 internationally.Confirmed the T2SARS-CoV-2TM Panel is capable of detecting the India B.1.617 variant of the SARS-CoV-2 virus based on sequence alignments and in silico analysis.Shares +29% AH.Press Release
For further details see:
T2 Biosystems reports Q1 results